Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 34th Annual Piper Sandler Healthcare Conference at 1:50 p.m. ET on Thursday, December 1, 2022, in New York City as well as host one-on-one meetings throughout the day.
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit https://tvarditherapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005184/en/
Source: Tvardi Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20221129005184/en
